Patents by Inventor Tod STRUGNELL

Tod STRUGNELL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN METAPNEUMOVIRUS VIRAL VECTOR-BASED VACCINES
    Publication number: 20240415952
    Abstract: The present disclosure provides a human metapneumovirus (hMPV) vaccine comprising an hMPV F protein antigen, and methods of eliciting an immune response by administering said vaccine.
    Type: Application
    Filed: May 22, 2024
    Publication date: December 19, 2024
    Inventors: Yvonne CHAN, Sukanya SASMAL, Antonia STUEBLER, Michael KISHKO, Sophia MUNDLE, Linong ZHANG, Josh DINAPOLI, Judith ALAMARES-SAPUAY, Natalie ANOSOVA, Sudha CHIVUKULA, Hillary DANZ, Tod STRUGNELL, Rachel GROPPO, Peter COLLINS, Ursula BUCHHOLZ, Shirin MUNIR, Bibha DAHAL
  • TRUNCATED INFLUENZA NEURAMINIDASE AND METHODS OF USING THE SAME
    Publication number: 20240335525
    Abstract: Provided are modified influenza virus subtype 2 neuraminidase molecules lacking all or substantially all of the stalk region that form active, soluble tetrameric neuraminidase when expressed in host cells and vaccine compositions comprising the tetrameric neuraminidase or a nucleic acid encoding the modified monomeric influenza virus subtype 2 neuraminidase molecules that forms tetrameric NA when expressed in a cell. Also provided are methods of using the vaccine compositions to vaccinate or immunize a subject against influenza virus.
    Type: Application
    Filed: August 10, 2022
    Publication date: October 10, 2024
    Inventors: Mario BARRO, Yvonne CHAN, Guadalupe CORTES-GARCIA, Raul GOMILA, Liqun HAN, Justin KLEKOTA, Fuqin MA, Satyajit RAY, Svetlana STEGALKINA, Tod STRUGNELL, Irina USTYUGOVA, Thorsten VOGEL, Jianxin ZHANG
  • ENGINEERED INFLUENZA ANTIGENIC POLYPEPTIDES AND IMMUNOGENIC COMPOSITIONS THEREOF
    Publication number: 20220242918
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Application
    Filed: April 11, 2022
    Publication date: August 4, 2022
    Inventors: Tod STRUGNELL, Eliud OLOO, Raymond OOMEN
  • METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING HEMAGGLUTININ
    Publication number: 20210128715
    Abstract: The present disclosure relates to a cluster-based consensus approach for generating recombinant hemagglutinin (HA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant HA polypeptides.
    Type: Application
    Filed: March 27, 2019
    Publication date: May 6, 2021
    Applicant: Sanofi Pasteur Inc.
    Inventors: Tod STRUGNELL, Eliud OLOO, Raymond OOMEN, Thorsten VOGEL, Harold KLEANTHOUS
  • ENGINEERED INFLUENZA ANTIGENIC POLYPEPTIDES AND IMMUNOGENIC COMPOSITIONS THEREOF
    Publication number: 20180298063
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Application
    Filed: June 2, 2016
    Publication date: October 18, 2018
    Inventors: Tod STRUGNELL, Eliud OLOO, Raymond OOMEN